287 related articles for article (PubMed ID: 18391694)
1. SFCE (Société Française de Lutte contre les Cancers et Leucémies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey.
Bertrand Y; Mechinaud F; Brethon B; Mialou V; Auvrignon A; Nelken B; Notz-Carrère A; Plantaz D; Patte C; Urbieta M; Baruchel A; Leverger G;
J Pediatr Hematol Oncol; 2008 Apr; 30(4):267-71. PubMed ID: 18391694
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
[No Abstract] [Full Text] [Related]
3. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
Kennedy LD; Ajiboye VO
J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
[TBL] [Abstract][Full Text] [Related]
4. Fixed-dose rasburicase 6 mg for hyperuricemia and tumor lysis syndrome in high-risk cancer patients.
Vines AN; Shanholtz CB; Thompson JL
Ann Pharmacother; 2010 Oct; 44(10):1529-37. PubMed ID: 20841516
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of rasburicase (recombinant urate oxidase) in the prevention and treatment of malignancy-associated hyperuricemia: an Indian experience.
Digumarti R; Sinha S; Nirni SS; Patil SG; Pedapenki RM
Indian J Cancer; 2014; 51(2):180-3. PubMed ID: 25104205
[TBL] [Abstract][Full Text] [Related]
6. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults.
McDonnell AM; Lenz KL; Frei-Lahr DA; Hayslip J; Hall PD
Pharmacotherapy; 2006 Jun; 26(6):806-12. PubMed ID: 16716134
[TBL] [Abstract][Full Text] [Related]
7. Pan-European multicentre economic evaluation of recombinant urate oxidase (rasburicase) in prevention and treatment of hyperuricaemia and tumour lysis syndrome in haematological cancer patients.
Annemans L; Moeremans K; Lamotte M; Garcia Conde J; van den Berg H; Myint H; Pieters R; Uyttebroeck A
Support Care Cancer; 2003 Apr; 11(4):249-57. PubMed ID: 12673464
[TBL] [Abstract][Full Text] [Related]
8. Clarifying the role of rasburicase in tumor lysis syndrome.
Sood AR; Burry LD; Cheng DK
Pharmacotherapy; 2007 Jan; 27(1):111-21. PubMed ID: 17192165
[TBL] [Abstract][Full Text] [Related]
9. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
[TBL] [Abstract][Full Text] [Related]
10. Risk-based management strategy and outcomes of tumor lysis syndrome in children with leukemia/lymphoma: Analysis from a resource-limited setting.
Gopakumar KG; Seetharam S; Km JK; Nair M; Rajeswari B; Cs G; Vr P; Thankamony P
Pediatr Blood Cancer; 2018 Dec; 65(12):e27401. PubMed ID: 30101454
[TBL] [Abstract][Full Text] [Related]
11. Rasburicase (recombinant urate oxidase) for the management of hyperuricemia in patients with cancer: report of an international compassionate use study.
Bosly A; Sonet A; Pinkerton CR; McCowage G; Bron D; Sanz MA; Van den Berg H
Cancer; 2003 Sep; 98(5):1048-54. PubMed ID: 12942574
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
Gupta G; Seth T; Garg V; Juneja R; Mahapatra M; Datta SK; Upadhyay AD; Saxena R
Clin Lymphoma Myeloma Leuk; 2021 Jan; 21(1):e99-e104. PubMed ID: 33039358
[TBL] [Abstract][Full Text] [Related]
13. Rasburicase in the prevention and treatment of tumour lysis syndrome.
Mayne N; Keady S; Thacker M
Intensive Crit Care Nurs; 2008 Feb; 24(1):59-62. PubMed ID: 17698360
[TBL] [Abstract][Full Text] [Related]
14. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
[TBL] [Abstract][Full Text] [Related]
15. Comparative evaluation of single fixed dosing and weight-based dosing of rasburicase for tumor lysis syndrome.
McBride A; Lathon SC; Boehmer L; Augustin KM; Butler SK; Westervelt P
Pharmacotherapy; 2013 Mar; 33(3):295-303. PubMed ID: 23456733
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of recombinant urate oxidase (rasburicase) for treatment and prophylaxis of hyperuricemia in children undergoing chemotherapy.
Pession A; Barbieri E; Santoro N; Paolucci P; Porta F; Locatelli F
Haematologica; 2005 Jan; 90(1):141-2. PubMed ID: 15642687
[TBL] [Abstract][Full Text] [Related]
17. Assessment of rasburicase utilization for tumor lysis syndrome management in pediatric and adult patients in the inpatient and outpatient settings.
Abousaud MI; Rush MC; Rockey M
J Oncol Pharm Pract; 2021 Jul; 27(5):1165-1171. PubMed ID: 32727320
[TBL] [Abstract][Full Text] [Related]
18. Single 6-mg dose of rasburicase: The experience in a large academic medical center.
Nauffal M; Redd R; Ni J; Stone RM; DeAngelo DJ; McDonnell AM
J Oncol Pharm Pract; 2019 Sep; 25(6):1349-1356. PubMed ID: 30111244
[TBL] [Abstract][Full Text] [Related]
19. Comparison of fixed versus traditional weight-based dosing of rasburicase in a pediatric population.
Savva DA; Herrera N; Rohatgi R
Pediatr Blood Cancer; 2018 Oct; 65(10):e27236. PubMed ID: 29905398
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome.
Knoebel RW; Lo M; Crank CW
J Oncol Pharm Pract; 2011 Sep; 17(3):147-54. PubMed ID: 20332174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]